NCT05024045 2026-03-03Study of Oral LOXO-338 in Patients With Advanced Blood CancersEli Lilly and CompanyPhase 1 Active not recruiting316 enrolled
NCT04849416 2026-02-06A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)Eli Lilly and CompanyPhase 2 Completed87 enrolled 19 charts
NCT03740529 2026-01-27A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHLEli Lilly and CompanyPhase 1/2 Completed803 enrolled 2 FDA
NCT05172700 2024-12-18Expanded Access Program for Pirtobrutinib for Participants With B-Cell CancerEli Lilly and CompanyApproved for marketing